JP2018528931A5 - - Google Patents

Info

Publication number

JP2018528931A5

JP2018528931A5 JP2018500700A JP2018500700A JP2018528931A5 JP 2018528931 A5 JP2018528931 A5 JP 2018528931A5 JP 2018500700 A JP2018500700 A JP 2018500700A JP 2018500700 A JP2018500700 A JP 2018500700A JP 2018528931 A5 JP2018528931 A5 JP 2018528931A5

Authority

JP

Japan

Prior art keywords

ethoxy

compound

carboxy

solvate

salt

Prior art date

2016-07-08

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 150000001875 compounds Chemical class 0.000 claims 46
• 150000003839 salts Chemical class 0.000 claims 20
• 239000012453 solvate Substances 0.000 claims 20
• -1 pentadecanyl Chemical group 0.000 claims 16
• 125000000539 amino acid group Chemical group 0.000 claims 11
• 239000003112 inhibitor Substances 0.000 claims 10
• QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims 7
• 208000008589 Obesity Diseases 0.000 claims 7
• 239000003814 drug Substances 0.000 claims 7
• 235000020824 obesity Nutrition 0.000 claims 6
• 239000013543 active substance Substances 0.000 claims 4
• 108090000765 processed proteins & peptides Proteins 0.000 claims 4
• 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 4
• DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims 3
• 206010020772 Hypertension Diseases 0.000 claims 3
• 239000004480 active ingredient Substances 0.000 claims 3
• 239000000556 agonist Substances 0.000 claims 3
• 206010012601 diabetes mellitus Diseases 0.000 claims 3
• 201000001421 hyperglycemia Diseases 0.000 claims 3
• NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 3
• 238000000034 method Methods 0.000 claims 3
• 239000008194 pharmaceutical composition Substances 0.000 claims 3
• 201000001320 Atherosclerosis Diseases 0.000 claims 2
• 208000032928 Dyslipidaemia Diseases 0.000 claims 2
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 2
• 206010018429 Glucose tolerance impaired Diseases 0.000 claims 2
• 208000017170 Lipid metabolism disease Diseases 0.000 claims 2
• 229940079593 drug Drugs 0.000 claims 2
• 230000000694 effects Effects 0.000 claims 2
• 239000008103 glucose Substances 0.000 claims 2
• 230000002265 prevention Effects 0.000 claims 2
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
• VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 claims 1
• ROJNYKZWTOHRNU-UHFFFAOYSA-N 2-chloro-4,5-difluoro-n-[[2-methoxy-5-(methylcarbamoylamino)phenyl]carbamoyl]benzamide Chemical compound CNC(=O)NC1=CC=C(OC)C(NC(=O)NC(=O)C=2C(=CC(F)=C(F)C=2)Cl)=C1 ROJNYKZWTOHRNU-UHFFFAOYSA-N 0.000 claims 1
• IGRCWJPBLWGNPX-UHFFFAOYSA-N 3-(2-chlorophenyl)-n-(4-chlorophenyl)-n,5-dimethyl-1,2-oxazole-4-carboxamide Chemical compound C=1C=C(Cl)C=CC=1N(C)C(=O)C1=C(C)ON=C1C1=CC=CC=C1Cl IGRCWJPBLWGNPX-UHFFFAOYSA-N 0.000 claims 1
• DGENZVKCTGIDRZ-UHFFFAOYSA-N 3-[4-[(3-phenoxyphenyl)methylamino]phenyl]propanoic acid Chemical compound C1=CC(CCC(=O)O)=CC=C1NCC1=CC=CC(OC=2C=CC=CC=2)=C1 DGENZVKCTGIDRZ-UHFFFAOYSA-N 0.000 claims 1
• SWLAMJPTOQZTAE-UHFFFAOYSA-N 4-[2-[(5-chloro-2-methoxybenzoyl)amino]ethyl]benzoic acid Chemical class COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(C(O)=O)C=C1 SWLAMJPTOQZTAE-UHFFFAOYSA-N 0.000 claims 1
• AJJISMLYIMQAKP-OAHLLOKOSA-N 5-[4-[(2r)-4-(3-fluoro-4-methylsulfonylphenoxy)butan-2-yl]piperidin-1-yl]-3-propan-2-yl-1,2,4-oxadiazole Chemical compound CC(C)C1=NOC(N2CCC(CC2)[C@H](C)CCOC=2C=C(F)C(=CC=2)S(C)(=O)=O)=N1 AJJISMLYIMQAKP-OAHLLOKOSA-N 0.000 claims 1
• 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims 1
• 229940123208 Biguanide Drugs 0.000 claims 1
• OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 claims 1
• 229940127291 Calcium channel antagonist Drugs 0.000 claims 1
• 206010007558 Cardiac failure chronic Diseases 0.000 claims 1
• 102100036869 Diacylglycerol O-acyltransferase 1 Human genes 0.000 claims 1
• 108050004099 Diacylglycerol O-acyltransferase 1 Proteins 0.000 claims 1
• 102100027844 Fibroblast growth factor receptor 4 Human genes 0.000 claims 1
• 101710182387 Fibroblast growth factor receptor 4 Proteins 0.000 claims 1
• 102100040134 Free fatty acid receptor 4 Human genes 0.000 claims 1
• 102000027487 Fructose-Bisphosphatase Human genes 0.000 claims 1
• 108010017464 Fructose-Bisphosphatase Proteins 0.000 claims 1
• 102100025353 G-protein coupled bile acid receptor 1 Human genes 0.000 claims 1
• 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims 1
• 229940100607 GPR119 agonist Drugs 0.000 claims 1
• 229940123483 GPR142 agonist Drugs 0.000 claims 1
• 229940125827 GPR40 agonist Drugs 0.000 claims 1
• 108091007911 GSKs Proteins 0.000 claims 1
• 102000051325 Glucagon Human genes 0.000 claims 1
• 108060003199 Glucagon Proteins 0.000 claims 1
• 108010063919 Glucagon Receptors Proteins 0.000 claims 1
• 102100040890 Glucagon receptor Human genes 0.000 claims 1
• 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 claims 1
• 102100032882 Glucagon-like peptide 1 receptor Human genes 0.000 claims 1
• 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 claims 1
• 102000030595 Glucokinase Human genes 0.000 claims 1
• 108010021582 Glucokinase Proteins 0.000 claims 1
• 208000002705 Glucose Intolerance Diseases 0.000 claims 1
• 102000003638 Glucose-6-Phosphatase Human genes 0.000 claims 1
• 108010086800 Glucose-6-Phosphatase Proteins 0.000 claims 1
• DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 1
• 102000004103 Glycogen Synthase Kinases Human genes 0.000 claims 1
• 206010019708 Hepatic steatosis Diseases 0.000 claims 1
• 101000890672 Homo sapiens Free fatty acid receptor 4 Proteins 0.000 claims 1
• 101000857733 Homo sapiens G-protein coupled bile acid receptor 1 Proteins 0.000 claims 1
• 102000004877 Insulin Human genes 0.000 claims 1
• 108090001061 Insulin Proteins 0.000 claims 1
• 206010022489 Insulin Resistance Diseases 0.000 claims 1
• 102000036770 Islet Amyloid Polypeptide Human genes 0.000 claims 1
• 108010041872 Islet Amyloid Polypeptide Proteins 0.000 claims 1
• 229940086609 Lipase inhibitor Drugs 0.000 claims 1
• 206010033307 Overweight Diseases 0.000 claims 1
• 101710176384 Peptide 1 Proteins 0.000 claims 1
• 229940086543 Phosphoenol pyruvate carboxykinase inhibitor Drugs 0.000 claims 1
• 208000001280 Prediabetic State Diseases 0.000 claims 1
• 102100040918 Pro-glucagon Human genes 0.000 claims 1
• LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 claims 1
• 108091006300 SLC2A4 Proteins 0.000 claims 1
• 108091006277 SLC5A1 Proteins 0.000 claims 1
• 108091006269 SLC5A2 Proteins 0.000 claims 1
• 102000058090 Sodium-Glucose Transporter 1 Human genes 0.000 claims 1
• 102000058081 Sodium-Glucose Transporter 2 Human genes 0.000 claims 1
• 229940123518 Sodium/glucose cotransporter 2 inhibitor Drugs 0.000 claims 1
• 102000005157 Somatostatin Human genes 0.000 claims 1
• 108010056088 Somatostatin Proteins 0.000 claims 1
• 208000006011 Stroke Diseases 0.000 claims 1
• 229940100389 Sulfonylurea Drugs 0.000 claims 1
• 229940123464 Thiazolidinedione Drugs 0.000 claims 1
• 101710204865 Tyrosine-protein phosphatase 1 Proteins 0.000 claims 1
• 238000010521 absorption reaction Methods 0.000 claims 1
• 239000012190 activator Substances 0.000 claims 1
• 239000000670 adrenergic alpha-2 receptor antagonist Substances 0.000 claims 1
• 239000003888 alpha glucosidase inhibitor Substances 0.000 claims 1
• 229940121369 angiogenesis inhibitor Drugs 0.000 claims 1
• 239000004037 angiogenesis inhibitor Substances 0.000 claims 1
• 230000000692 anti-sense effect Effects 0.000 claims 1
• 230000036528 appetite Effects 0.000 claims 1
• 235000019789 appetite Nutrition 0.000 claims 1
• 150000004283 biguanides Chemical class 0.000 claims 1
• 239000008280 blood Substances 0.000 claims 1
• 210000004369 blood Anatomy 0.000 claims 1
• 229960002802 bromocriptine Drugs 0.000 claims 1
• OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 claims 1
• 239000000480 calcium channel blocker Substances 0.000 claims 1
• 235000019577 caloric intake Nutrition 0.000 claims 1
• 125000004432 carbon atom Chemical group C* 0.000 claims 1
• 239000002604 chemokine receptor CCR2 antagonist Substances 0.000 claims 1
• 208000012696 congenital leptin deficiency Diseases 0.000 claims 1
• 208000029078 coronary artery disease Diseases 0.000 claims 1
• HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 claims 1
• 229960004166 diltiazem Drugs 0.000 claims 1
• 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 claims 1
• 201000010099 disease Diseases 0.000 claims 1
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
• 239000003937 drug carrier Substances 0.000 claims 1
• 229940127257 dual PPAR agonist Drugs 0.000 claims 1
• 230000009977 dual effect Effects 0.000 claims 1
• 235000005686 eating Nutrition 0.000 claims 1
• 230000037406 food intake Effects 0.000 claims 1
• 235000012631 food intake Nutrition 0.000 claims 1
• 230000002496 gastric effect Effects 0.000 claims 1
• 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
• MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims 1
• 229960004666 glucagon Drugs 0.000 claims 1
• 108010063245 glucagon-like peptide 1 (7-36)amide Proteins 0.000 claims 1
• 125000005842 heteroatom Chemical group 0.000 claims 1
• 239000003395 histamine H3 receptor antagonist Substances 0.000 claims 1
• 229940125396 insulin Drugs 0.000 claims 1
• 230000000968 intestinal effect Effects 0.000 claims 1
• 229940043355 kinase inhibitor Drugs 0.000 claims 1
• 229950004994 meglitinide Drugs 0.000 claims 1
• 239000000203 mixture Substances 0.000 claims 1
• 208000001022 morbid obesity Diseases 0.000 claims 1
• 208000030613 peripheral artery disease Diseases 0.000 claims 1
• 239000003757 phosphotransferase inhibitor Substances 0.000 claims 1
• 201000009104 prediabetes syndrome Diseases 0.000 claims 1
• 238000002360 preparation method Methods 0.000 claims 1
• 102000004196 processed proteins & peptides Human genes 0.000 claims 1
• 102000016670 prohibitin Human genes 0.000 claims 1
• 108010028138 prohibitin Proteins 0.000 claims 1
• 230000001737 promoting effect Effects 0.000 claims 1
• 238000010532 solid phase synthesis reaction Methods 0.000 claims 1
• NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims 1
• 229960000553 somatostatin Drugs 0.000 claims 1
• 230000009885 systemic effect Effects 0.000 claims 1
• 230000008685 targeting Effects 0.000 claims 1
• 150000001467 thiazolidinediones Chemical class 0.000 claims 1
• 239000003174 triple reuptake inhibitor Substances 0.000 claims 1
• 230000004584 weight gain Effects 0.000 claims 1
• 235000019786 weight gain Nutrition 0.000 claims 1
• 230000004580 weight loss Effects 0.000 claims 1